Bruce Carlsonbruce.carlson@kaloramainformation.comInfectiousInfectious disease world market to reach $4.9B in 2026: KaloramaAlthough COVID-19 and monkeypox dominate the headlines, numerous other known infectious diseases also threaten world populations.October 14, 2022Technology Commercialization$54B U.S. IVD market to grow 2% per year for five years: KaloramaTest makers will need to get creative for growth, and they can do so by focusing on a few growth-rich segments, such as point-of-care products and tissue diagnosticsOctober 11, 2022Technology CommercializationContract manufacturing market for IVD products to reach $16.1B in 2022: KaloramaEvolving trends in IVD contract manufacturing will result in developed economies retaining more than three-fourths of the total global demand.October 4, 2022ConsumerBoosted by COVID-19 and cancer tests, IVD market reaches $127B: KaloramaThat's the finding from Kalorama's market research report, The Worldwide Market for In Vitro Diagnostics, 15th edition.August 25, 2022PCRLaboratories stand ready if needed for monkeypox threatThe monkeypox virus is a relative of the smallpox virus that's weaker in severity and transmission than smallpox and that can be detected with PCR. The first draft genome from a swab of a confirmed case was published last week; this will allow the development of PCR tests for detecting the virus from scabs or blisters of potentially infected people. Testing is already available at the U.S. Centers for Disease Control and Prevention (CDC) and in major world laboratories. At least one IVD vendor has acted promptly with this disease event: on Wednesday, May 25, Roche Diagnostics announced it has launched a monkeypox PCR test.May 25, 2022Business Insights10 reasons for growth in the market for infectious disease testingMay 17, 2022Point-of-Care TestingCOVID drives 10X growth in molecular point-of-care marketThe 2021 figure represents 10 times growth in revenues from 2019, when molecular diagnostics were primarily being used by urgent care centers to determine flu and for hospitals looking to reduce antibiotic prescription. The COVID-19 pandemic and constant arrival of variants are the determining factor, and the continued presence of COVID will be a factor in the market.April 13, 2022Blood ClotsRevenues from coagulation lab and POC tests near $4B in 2021Hemostasis (coagulation) is a complex process in which multiple enzymes and proteins regulate blood flow and clot formation. Coagulation (clot formation), fibrinolysis (the breakup of blood clots), and platelet aggregation are a part of this process.February 15, 2022Pathology, histologyDigital pathology recovers from COVID setbackThe digital pathology market, which consists of hardware, software, and related services for clinical applications, has largely benefitted from the COVID-19 pandemic, allowing pathologist to read, evaluate, and collaborate remotely, improving efficiency and productivity.February 2, 2022Gastrointestinal DiseaseHow will the Quidel, Ortho deal impact the point-of-care market?The company that can impact the point-of-care market drives the future. The COVID-19 pandemic made that point visible, but the point-of-care sector was always significant, even before the pandemic. Point-of-care markets (and the companies that served them) grew faster than other markets.January 3, 2022Previous PagePage 2 of 7Next PageTop StoriesRegulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysThe newly certified assays include eight for gastrointestinal infections, seven for women's diseases, five for respiratory diseases, four for tuberculosis, three for meningitis, two for human papillomavirus (HPV), and one for drug resistance.Policy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsCOVID-19Long COVID symptoms reported by 17% of unvaccinated peopleSponsor ContentVisit our Molecular Diagnostics Community
